-  Increased baseline risk of osteosarcoma<br/><br/>          -  History of unresolved skeletal diseases affecting bone metabolism other than primary<br/>             osteoporosis<br/><br/>          -  Abnormally elevated serum calcium at screening<br/><br/>          -  Abnormally elevated serum intact parathyroid hormone (PTH) (1-84) at screening<br/><br/>          -  Severe vitamin D deficiency at screening<br/><br/>          -  Active liver disease or jaundice<br/><br/>          -  Significantly impaired renal function<br/><br/>          -  Abnormal thyroid function not corrected by therapy<br/><br/>          -  History of malignant neoplasm in the 5 years prior to screening<br/><br/>          -  History of bone marrow or solid organ transplantation<br/><br/>          -  History of symptomatic nephrolithiasis or urolithiasis in the 1 year prior to<br/>             screening<br/><br/>          -  Previous treatment with the following bone active drugs is allowed but must be<br/>             discontinued at screening: oral bisphosphonates, selective estrogen receptor<br/>             modulators (SERMs), calcitonin, estrogen (oral, transdermal, or injectable),<br/>             progestin, estrogen analog, estrogen agonist, estrogen antagonist or tibolone, and<br/>             active vitamin D3 analogs. Androgen or other anabolic steroid use must be<br/>             discontinued, except for use of physiologic replacement testosterone<br/><br/>          -  Previous treatment with the following bone active drugs is exclusionary, if the<br/>             stated treatment durations have been met: strontium ranelate for any duration,<br/>             intravenous bisphosphonates in the 12 months preceding screening, and/or denosumab in<br/>             the 6 months preceding screening<br/><br/>          -  Prior treatment with PTH, teriparatide, or other PTH analogs, or prior participation<br/>             in any other clinical trial studying PTH, teriparatide, or other PTH analogs<br/><br/>          -  Local or systemic treatment with bone morphogenic proteins or any other growth factor<br/><br/>          -  Previous fracture(s) or bone surgery in the currently fractured hip<br/><br/>          -  Soft-tissue infection at the operation site<br/><br/>          -  Treatment with bone grafting or osteotomies<br/><br/>          -  Treatment with augmentation using any type of degradable cement,<br/>             hydroxyapatite-coated implants, or with noninvasive interventions<br/><br/>          -  Associated major injuries of a lower extremity including fractures of the foot,<br/>             ankle, tibia, fibula, knee, femur, femoral head, or pelvis; dislocations of the<br/>             ankle, knee, or hip<br/>